Managing palmoplantar keratoderma: From diagnosis to therapy.

Nada Taylor*

Department of Dermatology, University of California, California

Introduction

Palmoplantar keratoderma (PPK) refers to a group of dermatological conditions characterized by thickened, hardened skin on the palms of the hands and soles of the feet. This disorder, which may be inherited or acquired, can range in severity and presentation, with some individuals experiencing mild symptoms and others facing significant disability due to the pain and mobility limitations it causes. Managing palmoplantar keratoderma requires a comprehensive approach that includes accurate diagnosis, appropriate treatment options, and ongoing care. In this article, we explore the key aspects of diagnosing and managing this condition, from initial evaluation to advanced therapeutic strategies [1].

Palmoplantar keratoderma encompasses a group of conditions marked by abnormal keratin production, leading to the thickening of the skin on the palms and soles. This condition can be either hereditary or acquired. Hereditary PPK often presents at an early age and can be inherited in an autosomal dominant or recessive pattern, depending on the specific subtype. Acquired forms of PPK may develop later in life and are often associated with other underlying health conditions, such as systemic diseases, infections, or certain medications [2].

While the primary symptom is the thickening of the skin, patients may also experience additional manifestations such as pain, cracking, or the formation of calluses. In severe cases, the condition can lead to difficulty in walking or performing manual tasks due to the discomfort caused by thickened skin [3].

The diagnosis of palmoplantar keratoderma begins with a thorough clinical examination. Dermatologists assess the appearance and distribution of skin lesions, considering the patient's medical history, family history, and any known underlying conditions that might contribute to the development of PPK [4].

In addition to clinical examination, a skin biopsy is often performed to examine the structure of the skin at a cellular level. Histological analysis can confirm the diagnosis and differentiate between hereditary and acquired forms. Genetic testing may also be used to identify specific mutations in cases of hereditary PPK, which can help with diagnosis, prognosis, and counselling [5].

Managing palmoplantar keratoderma requires a multifaceted approach, with treatments aimed at alleviating symptoms, improving the appearance of the skin, and addressing the underlying cause when applicable. The treatment plan may vary depending on the severity of the condition, the type of PPK, and the presence of associated comorbidities [6].

The physical appearance and associated discomfort of palmoplantar keratoderma can have a significant psychological impact, particularly when the condition affects the hands and feet, which are highly visible and essential for daily functioning. Patients may experience anxiety, embarrassment, or depression due to the impact on their self-esteem and ability to perform normal activities [7].

Supportive counseling and psychotherapy can be helpful for individuals struggling with the emotional effects of the condition. Additionally, patient support groups can provide an opportunity for individuals to connect with others facing similar challenges [8].

For patients with hereditary forms of palmoplantar keratoderma, genetic counseling is recommended. Since many forms of PPK are inherited, understanding the genetic basis of the disease can help patients and their families make informed decisions about family planning. Prenatal testing and pre-implantation genetic diagnosis (PGD) may be considered in certain cases where hereditary PPK is a concern [9].

Palmoplantar keratoderma is often a chronic condition that requires ongoing management. Regular follow-up visits with a dermatologist are important for monitoring the effectiveness of treatment, adjusting therapies as necessary, and managing any complications that arise. Patients with hereditary PPK may require lifelong management, while those with acquired forms may see improvement once the underlying condition is treated or controlled [10].

Conclusion

Palmoplantar keratoderma presents unique challenges for both patients and healthcare providers. Effective management hinges on a thorough diagnosis, personalized treatment plans, and a multidisciplinary approach that addresses both the physical and emotional aspects of the condition. While there is no cure for PPK, a combination of topical therapies, systemic treatments, and supportive measures can significantly improve quality of life and reduce symptoms. With advancements in treatment options and ongoing research into the genetic and environmental factors contributing to the condition, the future for patients with palmoplantar keratoderma looks promising.

***Correspondence to:** Nada Taylor, Department of Dermatology, University of California, California, E-mail: nada.taylor@gmail.com

***Received:** 1-May-2025, Manuscript No. aarcd-25-164964; **Editor assigned:** 5-May-2025, PreQC No. aarcd-25-164964 (PQ); **Reviewed:** 17-May-2025, QC No. aarcd-25-164964; **Revised**: 24-May-2025, Manuscript No. aarcd-25-164964 (R); **Published**: 31-May-2025, DOI:10.35841/aarcd-8.3.262.*

***Citation:** Taylor N. Managing palmoplantar keratoderma: From diagnosis to therapy. Res Clin Dermatol. 2025;8(3):262.*

References

1. Bodemer C, Steijlen P, Mazereeuw-Hautier J, et al. Treatment of hereditary palmoplantar keratoderma: A review by analysis of the literature. Br J Dermatol. 2021;184(3):393-400.
2. Dev T, Mahajan VK, Sethuraman G. Hereditary palmoplantar keratoderma: A practical approach to the diagnosis. Indian Dermatol Online J. 2019;10(4):365-79.
3. Yoneda K, Kubo A, Nomura T, et al. Japanese guidelines for the management of palmoplantar keratoderma. J Dermatol. 2021;48(8):e353-67.
4. Patel S, Zirwas M, English JC. Acquired palmoplantar keratoderma. Am J Clin Dermatol. 2007;8:1-1.
5. Porter RM, Bravo AA, Smith FJ. Management of plantar keratodermas: Lessons from pachyonychia congenita. J Am Podiatr Med Assoc. 2017;107(5):428-35.
6. Zieman AG, Coulombe PA. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: New insights into skin epithelial homeostasis and avenues for treatment. Br J Dermatol. 2020;182(3):564-73.
7. SS VA, Rakshith UR, Srikanth MS. A Review on Palmoplantar keratodermas. Int J Pharm Sci Nanotechnol. 2022;15(6):6258-31.
8. Sharquie KE, Abdulwahhab W. Keratoderma of palms and soles is an umbrella for the first manifestation of different skin diseases. J Pak Assoc Dermatol. 2023;33(2):559-65.
9. Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol. 2012;51(10):1195-8.
10. Greco C, Ponsen AC, Leclerc-Mercier S, et al. Treatment of painful palmoplantar keratoderma related to pachyonychia congenita using EGFR inhibitors. Biomedicine. 2022;10(4):841.

Citation: *Taylor N. Managing palmoplantar keratoderma: From diagnosis to therapy. Res Clin Dermatol. 2025;8(3):262.*